Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch

01 Nov 2022

The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.

Tirzepatide may soon compete with semaglutide in two major indications • Source: Shutterstock

Launch metrics for Eli Lilly and Company’s GIP/GLP-1 analog Mounjaro (tirzepatide) in type 2 diabetes are exceeding expectations to this point, and the pharma reported during its 1 November earnings call that commercial coverage in the US increased significantly during the third quarter. Perhaps mindful of the supply issues faced by competitor Novo Nordisk A/S with Ozempic/Wegovy (semaglutide), Lilly is trying to prepare for high demand for the product in two major indications ahead of the planned submission for obesity in 2023.

The GIP/GLP-1 analog launched during the second quarter and brought in $187.3m during Q3, comprised of $97.3m in domestic sales and $90m in revenue sharing from Japanese commercialization partner Mitsubishi Tanabe Pharma Corporation. (Also see "Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise" - Scrip, 13 May, 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

06 May 2025

• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

02 May 2025

• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

Transient FY26 For Syngene But Momentum In China +1 Projects

02 May 2025

• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.